Timothy Best, Ph.D.
About Timothy Best, Ph.D.
Timothy Best, Ph.D., serves as the Senior Director of Global Medical Affairs at Kite Pharma, bringing extensive experience from previous leadership roles at Juno, Celgene, and Bristol Myers Squibb, particularly in CAR T and CELMoD franchises for lymphoma and multiple myeloma.
Work at Kite Pharma
Timothy Best serves as the Senior Director of Global Medical Affairs at Kite Pharma. He has held this position since 2022, contributing to the company's strategic initiatives in medical affairs. His role involves overseeing the development and implementation of medical strategies that align with Kite's objectives in the biopharmaceutical sector.
Previous Leadership Roles
Before joining Kite Pharma, Timothy Best held significant leadership positions at Juno Therapeutics, Celgene, and Bristol Myers Squibb (BMS). His focus was primarily on the CAR T and CELMoD franchises, particularly in the areas of lymphoma and multiple myeloma. These roles allowed him to gain extensive experience in the oncology field.
Medical Science Liaison Experience
Timothy Best has experience leading a medical science liaison team, which enhances his comprehensive approach to medical affairs. His previous role as a Medical Science Liaison at Ipsen from 2015 to 2016 provided him with insights into clinician engagement and the importance of integrating feedback into drug development processes.
Education and Expertise
Timothy Best completed his undergraduate studies at Penn State University, earning a B.S. in Biochemistry and Molecular Biology with honors from 2003 to 2007. He furthered his education at the University of Chicago, where he obtained a Ph.D. in Cancer Biology from 2007 to 2012. His academic background supports his expertise in medical affairs and oncology.
Consulting and Strategic Development
Prior to his roles in medical affairs, Timothy Best worked as a consultant at Sg2 from 2013 to 2015. In this capacity, he developed healthcare professional engagement strategies aimed at incorporating clinician feedback into drug development and lifecycle management. This experience contributed to his strategic approach in his subsequent roles.